ACTH Inhibitors
1 drugsAbout ACTH
Adrenocorticotropic hormone (ACTH) is a peptide hormone produced by the anterior pituitary gland. It stimulates the adrenal cortex to release cortisol, regulating metabolism, immune response, and stress. The hypothalamic-pituitary-adrenal (HPA) axis highlights its significance.
ACTH's central role in cortisol regulation makes it a therapeutic target, particularly in immunology. However, there is currently no genetic evidence directly linking ACTH to specific diseases.
ACTH is targeted by one FDA-approved drug, H.P. ACTHAR GEL, a small molecule with 8 indications. QUESTCOR PHARMA is the primary company in this space, with H.P. ACTHAR GEL approved in 2010.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Drugs
QUESTCOR PHARMA is the only company with an approved drug targeting ACTH.
High market concentration indicates potential entry barriers, requiring strong IP or clinical advantages for new entrants.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ACTH, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer differentiation and novel therapeutic approaches.
Clinical Trials 78 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 10 | 2 | 1 | 83% |
| Phase 2 | 17 | 8 | 8 | 1 | 50% |
| Phase 3 | 12 | 10 | 0 | 2 | 100% |
| Phase 4 | 36 | 21 | 14 | 1 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2010 - 2010)
The first and only drug, H.P. ACTHAR GEL, was approved in 2010.
The stagnant approval timeline suggests a saturated market or challenges in developing new ACTH-modulating therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 41 clinical trials targeting ACTH.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities